Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:9/26/2008

d in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

As previously announced, the Company is evaluating the Company's research and development programs, including related assets and costs, and strategic alternatives available to the Company.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including the Company's belief that the data from the L-MTP-PE Phase 3 study warrants regulatory approval in Europe and the United States, the Company's plans to address the remaining questions with respect to the MAA for L-MTP-PE, including the Company's plans for completion of data analysis and submission of responses to the CHMP, the expected timing of a final opinion from the CHMP and receipt of a final regulatory decision regarding the MAA in
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
10. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 Today MedeAnalytics, a ... the next-generation of its Employer Group and ... plans to provide their employer groups an intuitive ... medical and prescription drug claims, network utilization, and ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group and ...
(Date:6/18/2013)... -- , Safinamide significantly improves responder ... add-on to levodopa Safinamide is associated ... fluctuating PD patients as add-on to levodopa ... a research and development company focused on novel ... S.p.A., a pharmaceutical company strongly committed to the ...
(Date:6/18/2013)... PROSPECT, Ill. , June 18, 2013 /PRNewswire-iReach/ ... of its new X3130 Appliance Inlet Module. The ... circuit breaker , combines a C14 appliance inlet ... one compact package.  This three-in-one device allows design ... their designs - cutting installation time by 66 ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Three-in-One X3130 Appliance Inlet Module 2
(Date:6/19/2013)... Raton, FL (PRWEB) June 19, 2013 At ... about the positive changes and growth that has occurred over ... nationwide travel club. , Shuman said, "Travel Services has added ... to heights beyond belief. Membership is up, even in ... to meet the demands of members." , Having been in ...
(Date:6/19/2013)... neuron disease Amyotrophic lateral sclerosis (ALS), also known as ... which can be classified into four distinct stages, report ... University of Pennsylvania in the Annals of Neurology ... cord tissues shows, for the first time, how the ... in the central nervous system to other regions of ...
(Date:6/19/2013)... molecule derived from a naturally occurring compound (apocynin), ... mice with Parkinson,s Disease symptoms by preventing deficits ... in the May 28, 2013 edition of ... Ph.D., postdoctoral fellow at the Medical College of ... paper. Balaraman Kalyanaraman, Ph.D., Harry R. & ...
(Date:6/19/2013)... Imprivata ®, a leading global provider of ... OneSign ® leads the single sign-on (SSO) category in ... Services report . CIOs and other healthcare executives iwere ... of its products and the quality of its customer ... integral to their long-term healthcare IT strategy. , ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 The US Food ... a third ultra cohesive gel breast implant, Mentor Worldwide’s MemoryShape™. ... 410 in February 2013. The FDA announced the approval of ... approved for primary augmentations in women 22 years ... any age. , The FDA’s approval comes after six ...
Breaking Medicine News(10 mins):Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2
... to the food chain via the Bernard Matthews plant, which ... in early February this year. , ,The Public ... turkey had to pass through the plant situated in Holton ... outbreak of the avian influenza and resumption of production services ...
... believe they may be on the right track ... key they say is stimulation of the occipital nerve. ... head and neck of the sufferers and giving them remotes ... reached separate research groups That included neurologists from the ...
... 8. According to statistics over one lac people Indians are ... cent die as they do not get timely treatment. ... Health Check-up package in connection with World Kidney Day-2007. The ... consultation and urine analysis for random glucose and creatinine. ...
... Want to de-stress, tone up your body or build your confidence? How ... and step on the dance floor// . ,'I tried going ... Then I started going for walks but I got bored of that ... stopped since,' said Suman Vohra, a doctor at the Apollo Hospital here. ...
... Implantable materials that grab stem cells and spur their ... and her colleagues// at MIT have created a new ... transplant environment--a key step in cell-transplant therapies. Scientists are ... well it can help heal fractures. ,"Creating ...
... schools and homes were housed under asbestos roofs. The children ... the repercussion of living their childhood days under asbestos roofs, ... cancer- Mesothelioma. Almost 5% of all lung cancers in the ... ,Mesothelioma is a medical term used to describe a cancer ...
Cached Medicine News:Health News:Doctors Put on Their Dancing Shoes to De-stress 2Health News:Healing Bone With Stem Cells 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: